DNLI Q3 2022 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-32.7% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$107M-3020.1% margin

Net Income

-$103M-2902.5% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

-93.2%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$63M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$416M

Stockholders' Equity

$811M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-32.7%
Gross Profit	$4M	$5M	-32.7%
Operating Income	-$107M	-$86M	-25.6%
Net Income	-$103M	-$85M	-22.1%